Skip to main content

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Publication ,  Journal Article
Scher, HI; Halabi, S; Tannock, I; Morris, M; Sternberg, CN; Carducci, MA; Eisenberger, MA; Higano, C; Bubley, GJ; Dreicer, R; Petrylak, D ...
Published in: J Clin Oncol
March 1, 2008

PURPOSE: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS: A committee of investigators experienced in conducting trials for prostate cancer defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and emerging trial data. RESULTS: The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving, or eliminating disease manifestations that are present when treatment is initiated and (2) preventing or delaying disease manifestations expected to occur. Prostate cancers progressing despite castrate levels of testosterone are considered castration resistant and not hormone refractory. Eligibility is defined using standard disease assessments to authenticate disease progression, prior treatment, distinct clinical subtypes, and predictive models. Outcomes are reported independently for prostate-specific antigen (PSA), imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response. In most trials, early changes in PSA and/or pain are not acted on without other evidence of disease progression, and treatment should be continued for at least 12 weeks to ensure adequate drug exposure. Bone scans are reported as "new lesions" or "no new lesions," changes in soft-tissue disease assessed by RECIST, and pain using validated scales. Defining eligibility for prevent/delay end points requires attention to estimated event frequency and/or random assignment to a control group. CONCLUSION: PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.

Duke Scholars

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 1, 2008

Volume

26

Issue

7

Start / End Page

1148 / 1159

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Testosterone
  • Research Design
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Patient Selection
  • Outcome Assessment, Health Care
  • Oncology & Carcinogenesis
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., … Prostate Cancer Clinical Trials Working Group, . (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol, 26(7), 1148–1159. https://doi.org/10.1200/JCO.2007.12.4487
Scher, Howard I., Susan Halabi, Ian Tannock, Michael Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, et al. “Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.J Clin Oncol 26, no. 7 (March 1, 2008): 1148–59. https://doi.org/10.1200/JCO.2007.12.4487.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148–1159.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 1, 2008

Volume

26

Issue

7

Start / End Page

1148 / 1159

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Testosterone
  • Research Design
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Patient Selection
  • Outcome Assessment, Health Care
  • Oncology & Carcinogenesis
  • Male
  • Humans